LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma

Liu, Fahui; Hou, Wanyun; Liang, Jiadong; Zhu, Lilan; Luo, Chunying

doi:10.7150/jca.53124



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(13):4039-4048. doi:10.7150/jca.53124 This issue Cite

Research Paper

LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma

Fahui Liu^1*, Wanyun Hou^1*, Jiadong Liang¹, Lilan Zhu², Chunying Luo^1,3✉

1. Department of Pathology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, Guangxi, PR China.
2. Youjiang Medical University for Nationalities, Baise 533000, Guangxi, PR China.
3. Medical College of Guangxi University, Nanning, 530004, Guangxi, PR China.
*These authors contributed equally to this work.

Citation:

Liu F, Hou W, Liang J, Zhu L, Luo C. LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma. J Cancer 2021; 12(13):4039-4048. doi:10.7150/jca.53124. https://www.jcancer.org/v12p4039.htm

Other styles

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies globally and the second leading cause of cancer-related death. Low-density lipoprotein (LDL) receptor-related protein 1B (LRP1B) is one of the commonly mutated genes in HCC, but its role in HCC remains unclear. In this study, we analyzed the role of LRP1B mutation in HCC. The bioinformatics results show that LRP1B had a frequency of mutation in HCC patients, and LRP1B mutation was associated with a higher tumor mutation burden (TMB), and survival analysis proved that the prognosis of HCC patients with LRP1B mutation was poor. Univariate and multivariate COX regression analysis indicated that LRP1B mutation was an independent risk factor in evaluating HCC patients' prognosis. Correlation analysis showed that LRP1B mutation status was associated with the infiltration of 2 types of immune cells and higher expression of immune checkpoint gene human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) in HCC patients. In summary, the results show that LRP1B mutation is associated with the higher TMB and poor prognosis of patients with HCC, and it was an independent risk factor for clinical outcomes of HCC patients. LRP1B gene mutations can serve as predictors in HCC patients with higher TMB and higher expression of HHLA2. The results of this study will be beneficial to future studies on targeted therapy and immunotherapy for HCC.

Keywords: hepatocellular carcinoma, bioinformatics, LRP1B, mutation, TMB, prognosis

Citation styles

APA

Liu, F., Hou, W., Liang, J., Zhu, L., Luo, C. (2021). LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma. Journal of Cancer, 12(13), 4039-4048. https://doi.org/10.7150/jca.53124.

ACS

Liu, F.; Hou, W.; Liang, J.; Zhu, L.; Luo, C. LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma. J. Cancer 2021, 12 (13), 4039-4048. DOI: 10.7150/jca.53124.

NLM

CSE

Liu F, Hou W, Liang J, Zhu L, Luo C. 2021. LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma. J Cancer. 12(13):4039-4048.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.